Compare BNL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | ELVN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 2008 | 2020 |
| Metric | BNL | ELVN |
|---|---|---|
| Price | $17.39 | $41.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $23.60 | ★ $73.92 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $454,138,000.00 | N/A |
| Revenue This Year | $8.13 | N/A |
| Revenue Next Year | $9.56 | N/A |
| P/E Ratio | $73.02 | ★ N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $17.13 | $14.79 |
| 52 Week High | $23.10 | $62.32 |
| Indicator | BNL | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 39.47 |
| Support Level | N/A | $37.77 |
| Resistance Level | $18.81 | $43.05 |
| Average True Range (ATR) | 0.44 | 1.84 |
| MACD | -0.01 | 0.57 |
| Stochastic Oscillator | 14.48 | 50.69 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.